生物技術領域的授權協議（2020-2026）

本報告對全球生物技術領域的授權協議進行研究和分析，深入探討了企業如何建立授權合作關係、協商財務條款以及分配開發和商業化權利。

目錄

摘要整理

第一章：引言

第二章：許可協議趨勢

• 引言
• 許可協議的定義
• 授權協議趨勢（2020年至今）
  • 許可協議：依年份
  • 許可協議：依研發階段
  • 授權協議：依行業
  • 許可協議：依治療領域
  • 授權協議：依技術類型
  • 最活躍公司的授權協議
• 簽訂許可合作協議的原因
• 許可的未來協議

第三章 許可合約架構概論

• 引言
• 許可合約結構

第四章：主要許可合約

• 引言
• 依價值排名的頂級許可合約

第五章：最活躍的25家授權公司

• 引言
• 最活躍的25家授權公司

第六章：許可合約（含合約目錄）

• 引言
• 許可合約及合約文件
• 合約目錄
• 合約目錄 - 許可合約：依公司分類 （A-Z）
• 合約目錄 - 許可合約：依治療領域分類
• 合約目錄 - 授權協議：依技術類型分類
• 關於 Biopharma Research Ltd
• 當前合作夥伴
• 當前協議
• 現任合作夥伴近期報告標題

Benchmark Licensing Partnerships Across the Global Biotechnology Industry

Free report sample

The Licensing Deals in Biotechnology 2020-2026 report provides a comprehensive analysis of licensing agreements across the global biotechnology sector. Designed for business development, licensing, legal, and strategy professionals, the report delivers detailed insight into how companies structure licensing partnerships, negotiate financial terms, and allocate development and commercialization rights.

Fully revised and updated, the report provides detailed information on 2,500+ biotechnology licensing deals announced between 2020 and 2026, offering a broad view of licensing activity across emerging technologies and therapeutic areas. Each transaction includes financial information where available and links to online deal records and contract documents filed with regulators when publicly disclosed.

By combining detailed deal data, financial benchmarking, and access to real contract agreements, the report provides valuable intelligence for evaluating partners, structuring licensing agreements, and negotiating stronger deal terms.

Key Benefits

• Save Significant Research Time

Access a comprehensive database of biotechnology licensing deals instead of searching multiple databases, press releases, and regulatory filings.

• Benchmark Licensing Deal Structures

Understand how biotechnology companies structure licensing partnerships, including development responsibilities, territorial rights, and commercialization arrangements.

• Analyze Financial Terms with Confidence

Review disclosed financial terms including upfront payments, milestone payments, and royalty structures, enabling accurate benchmarking of licensing deal value.

• Access Real Contract Documents

Where available, review actual licensing agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.

• Identify Active Licensing Dealmakers

Discover which biotechnology companies are most active in licensing partnerships and analyze their dealmaking strategies.

• Track Industry Trends

Analyze licensing activity since 2020 across companies, therapeutic areas, and technologies to understand how partnering strategies are evolving in the biotech sector.

What's Included in the Report

Analysis of biotechnology licensing dealmaking trends since 2020

Overview of licensing deal structures and financial models

Review of leading licensing deals by disclosed value

Profiles of the top 25 most active licensing dealmakers

Detailed analysis of deals organized by company, therapeutic area, technology type, and industry segment

A comprehensive deal directory covering licensing deals announced since 2020

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual licensing contracts, the report enables users to evaluate key partnership provisions such as:

• Rights granted or optioned under the license
• Upfront payments, milestones, and royalty structures
• Intellectual property ownership and licensing scope
• Development, manufacturing, and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration and termination clauses
• Analyzing these agreements provides valuable insight into how licensing partnerships are negotiated and structured across the biotechnology industry.
• Why This Report Matters
• Licensing partnerships are central to innovation in biotechnology, allowing companies to access new technologies, share development risk, and accelerate product development.
• By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to structure stronger licensing partnerships and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2020
  • 2.3.1. Licensing dealmaking by year
  • 2.3.2. Licensing dealmaking by phase of development
  • 2.3.3. Licensing dealmaking by industry sector
  • 2.3.4. Licensing dealmaking by therapy area
  • 2.3.5. Licensing dealmaking by technology type
  • 2.3.6. Licensing dealmaking by most active company
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements
• Figure 3: Licensing deals signed at each phase of development
• Figure 4: Licensing deals by industry sector
• Figure 5: Licensing deals by therapy area
• Figure 6: Licensing deals by technology type
• Figure 7: Top 25 most active licensing dealmakers
• Figure 8: Top licensing deals by value
• Figure 9: Most active licensing dealmakers